{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:22:44Z","timestamp":1695705764850},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of prostate cancer cells, which has led to the development of radiolabeled small-molecule inhibitors of PSMA for molecular imaging and targeted radioligand therapy. <jats:sup>177<\/jats:sup>Lu-labeled PSMA, with therapeutic \u03b2-emission and concomitant \u03b3 radiation, permits posttherapy imaging for the assessment of biodistribution and uptake in tumors and normal organs, as well as dosimetry. We report a patient with prostate cancer and metastatic lymph nodes\u2013related lower extremity lymphedema, who presented with dermal backflow and soft-tissue uptake in the lower extremity on posttherapeutic whole body scan after intravenous <jats:sup>177<\/jats:sup>Lu-PSMA treatment.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002552","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T14:11:29Z","timestamp":1554127889000},"page":"501-503","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema"],"prefix":"10.1097","volume":"44","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviral","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1148\/radiol.2018180788","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate cancer","volume":"289","year":"2018","journal-title":"Radiology"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.7150\/thno.20855","article-title":"PSMA-PET for lymph node detection in recurrent prostate cancer: how do we use the magic bullet?","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib4-20230925","first-page":"20180308","article-title":"Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen","volume":"9","year":"2018","journal-title":"Br J Radiol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00259-017-3676-6","article-title":"Microsurgery guided by sequential preoperative lymphography using 68Ga-NEB PET and MRI in patients with lower-limb lymphedema","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/RLU.0000000000001525","article-title":"Skeletal scintigraphy in radiation-induced fibrosis with lymphedema","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jvsv.2016.11.008","article-title":"Lymphoscintigraphic abnormalities in the contralateral lower limbs of patients with unilateral lymphedema","volume":"5","year":"2017","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11934-017-0696-5","article-title":"Therapeutic value of standard versus extended pelvic lymph node dissection during radical prostatectomy for high-risk prostate cancer","volume":"18","year":"2017","journal-title":"Curr Urol Rep"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","year":"1999","journal-title":"Eur J Cancer"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1196\/annals.1413.014","article-title":"Estimating the population burden of lymphedema","volume":"1131","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-fluid-122316-045259","article-title":"Lymphatic system flows","volume":"50","year":"2018","journal-title":"Annu Rev Fluid Mech"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:10:41Z","timestamp":1695618641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002552","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}